Terbinafine (Lamisil)
Terbinafine
Novartis South Africa (Pty) Ltd
Registration
- Applicant
- Novartis South Africa (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lamisil 250 MG EACH TABLET CONTAINS TERBINAFINE HYDROCHLORIDE EQUIVALENT TO 250 mg TERBINAFINE | 250 mg | Z0185Z/20.2.2/185 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Terbinafine
- except when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 8132
S1: Terbinafine
- when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 1094
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(E)-N,6,6-Trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
Drag to rotate. Structure from PubChem CID 1549008.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.